Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comprehensive patient evaluation for benign prostatic hyperplasia

J V Jepsen1, R C Bruskewitz

  • 1Department of Surgery, University of Wisconsin, Hospital and Clinics, Madison 53792, USA.

Urology
|May 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical and nonsurgical invasive treatment of benign prostatic hyperplasia.

Drugs of today (Barcelona, Spain : 1998)·2004
Same author

Economics of transurethral thermotherapy of the prostate.

World journal of urology·2002
Same author

Correlates of urinary symptom scores in men.

American journal of public health·1999
Same author

The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters: analysis of the United States randomized study.

The Journal of urology·1999
Same author

Impact of drug therapy on benign prostatic hyperplasia-specific quality of life.

Urology·1999
Same author

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group.

Urology·1999

New approaches to benign prostatic hyperplasia (BPH) are needed. Current BPH assessment methods may overlook bladder dysfunction, emphasizing patient bother over symptom scores for treatment decisions.

Area of Science:

  • Urology
  • Geriatrics
  • Men's Health

Background:

  • Benign prostatic hyperplasia (BPH) is traditionally linked to prostate enlargement, obstruction, and symptoms.
  • Current understanding recognizes distinct BPH components: benign prostatic enlargement (BPE), bladder outlet obstruction (BOO), and lower urinary tract symptoms (LUTS).
  • Existing assessment tools like symptom questionnaires, uroflowmetry, and volume measurements have limitations due to variability and may not fully capture the patient's experience.

Purpose of the Study:

  • To advocate for a paradigm shift in BPH management, focusing on bladder dysfunction and patient-reported bother.
  • To highlight the limitations of current diagnostic and treatment selection methods for BPH.
  • To emphasize the need for improved quantification of bladder dysfunction and its impact on quality of life.

Related Experiment Videos

Main Methods:

  • Review of current BPH assessment tools and their limitations.
  • Analysis of the relationship between prostate size, obstruction, bladder function, and LUTS.
  • Discussion of the role of patient-reported bother in treatment decision-making.

Main Results:

  • Bladder dysfunction significantly contributes to BPH symptomatology and is often underestimated.
  • Postvoid residual urine and uroflowmetry show high variability, limiting their predictive value.
  • Patient bother, rather than symptom scores or objective measures, is the primary driver for BPH treatment decisions.

Conclusions:

  • Future BPH management must prioritize the assessment and quantification of bladder dysfunction.
  • Treatment decisions should be centered on the degree of patient bother and impact on quality of life.
  • Rethinking BPH assessment and treatment is crucial, moving beyond solely prostate size and obstruction.